BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/18/2020 5:58:43 AM | Browse: 995 | Download: 2363
 |
Received |
|
2020-06-09 03:09 |
|
Peer-Review Started |
|
2020-06-09 03:11 |
|
First Decision by Editorial Office Director |
|
2020-09-18 16:46 |
|
Return for Revision |
|
2020-09-18 16:46 |
|
Revised |
|
2020-10-07 00:16 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-11-13 09:57 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-11-13 19:17 |
|
Articles in Press |
|
2020-11-13 19:17 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-12-04 08:23 |
|
Publish the Manuscript Online |
|
2020-12-18 05:58 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Muhammad Shafiq, Timothy Walmann, Venkat Nutalapati, Cheryl Gibson and Yousaf Zafar |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Muhammad Shafiq, MD, Assistant Professor, General and Geriatric Medicine, University of Kansas Medical Center, 4000 Cambridge Street, 6040 Delp & Mail Stop 1020, Kansas City, KS 66160, United States. mshafiq@kumc.edu |
| Key Words |
Proprotein convertase subtilisin/kexin type-9 inhibitor; Fatty liver; Nonalcoholic fatty liver disease; Alanine aminotransferase; Aspartate aminotransferase; Imaging |
| Core Tip |
This retrospective study evaluated the effects of proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors on fatty infiltration of the liver. Among the 29 selected patients, 11 were found to have radiologic diagnosis of hepatic steatosis and 8 of those (72.73%) achieved complete radiologic resolution of the condition upon use of PCSK9 inhibitors for mean duration of 17.6 mo. Both alanine aminotransferase and aspartate aminotransferase levels showed a downward trend after PCSK9 inhibitors for mean duration of 23.69 ± 11.18 mo. These results highlight the potential benefit of PCSK9 inhibitors use for patients with nonalcoholic fatty liver disease. |
| Publish Date |
2020-12-18 05:58 |
| Citation |
Shafiq M, Walmann T, Nutalapati V, Gibson C, Zafar Y. Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver. World J Hepatol 2020; 12(12): 1258-1266 |
| URL |
https://www.wjgnet.com/1948-5182/full/v12/i12/1258.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v12.i12.1258 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
